7-Days Water-Only Fasting Trial in Prostate Cancer
Part of paid clinical trials in Baltimore, Maryland.
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Study ID
- NCT06826924
- Status
- Recruiting
Conditions
- Metastatic Prostate Cancer
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Fasting — BEHAVIORAL7 days of water-only fasting
Study Details
Activating the immune system to kill cancer cells is a promising therapeutic strategy for some patients with cancer. Unfortunately, current immune-targeting treatments do not work for patients with prostate cancer. In animal models of cancer, fasting can reprogram the body's metabolism and immune cell function to help immune cells kill cancer cells. The purpose of this study is to determine whether 7 days of water-only fasting or a very low-calorie diet is safe and feasible for patients with metastatic prostate cancer. This will help the investigators develop future studies to test whether incorporating periods of fasting or very low calorie diets into treatment plans for prostate cancer can improve outcomes from this disease.
Key Dates
- Start date
- Jun 3, 2025
- Status verified
- Jul 2025
- Primary completion
- Jun 3, 2026
- Completion
- Jun 3, 2026
Study Design
- Enrollment
- 10 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Fasting7-day water-only fast followed by a 3-day refeeding
Primary Outcome Measure
Number of adverse events and serious adverse events (SAEs) [ Time Frame: 1 year ]
Central Contacts
- Laura Sena, MD, PhD410-502-3825
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | Maryland | 21231 | Laura Sena |
Find similar trials in Baltimore, MD
Related Studies
- Collection of Blood From Patients With Prostate CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate CancerPHASE2/PHASE3 · Recruiting · VA Office of Research and Development · Long Beach, California
- Study of ORIC-944 in Patients With Metastatic Prostate CancerPHASE1 · Recruiting · ORIC Pharmaceuticals · Colorado Springs, Colorado
- Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate CancerPHASE2 · Recruiting · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Baltimore, Maryland